Taysha Gene Therapies (TSHA) Expected to Announce Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA) is anticipated to release its earnings data before the market opens on Tuesday, March 18th. Analysts expect Taysha Gene Therapies to post earnings of ($0.08) per share and revenue of $2.05 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA opened at $1.72 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. The stock’s 50-day simple moving average is $1.65 and its 200 day simple moving average is $1.94. The company has a market cap of $352.60 million, a P/E ratio of 2.73 and a beta of 0.91. Taysha Gene Therapies has a 52-week low of $1.19 and a 52-week high of $4.32.

Analyst Upgrades and Downgrades

TSHA has been the topic of a number of recent research reports. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.